Update shared on13 Oct 2025
Everest Medicines' analyst price target has been adjusted downward from $29.16 to $26.79, reflecting analysts' moderated growth and profitability expectations in light of updated risk assessments.
What's in the News
- Everest Medicines provided earning guidance for the full year 2025, projecting revenue of RMB 1.6 billion to RMB 1.8 billion, with RMB 1.2 billion to RMB 1.4 billion expected from NEFECON sales (Key Developments).
- The company has scheduled a board meeting on August 28, 2025 to discuss interim results for the first half of 2025 and other business matters (Key Developments).
- Everest Medicines completed a follow-on equity offering and raised HKD 1.57 billion through the direct listing of over 22 million ordinary shares at HKD 69.7 per share (Key Developments).
- Certain ordinary shares are under a lock-up agreement ending on October 31, 2025. This restricts the company from new public offerings during this period without placement agents' consent (Key Developments).
Valuation Changes
- The discount rate has risen slightly from 6.90% to 6.98%, reflecting moderately higher perceived risk in the updated analysis.
- The future P/E has fallen from 29.16x to 26.79x, indicating a less optimistic outlook for future earnings multiples.
- The fair value estimate remains unchanged at 64.56, suggesting no adjustment in intrinsic valuation assumptions.
- The revenue growth projection is virtually unchanged, holding steady at 63.52%.
- The net profit margin projection remains consistent, staying at approximately 24.42%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.